Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Janone Inc (JAN)

Janone Inc (JAN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
JanOne to Present at the Dawson James 8th Annual Investment Conference PR Newswire - Thu Sep 21, 2023

/PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of...

JAN : 4.25 (-1.70%)
JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference PR Newswire - Thu Aug 31, 2023

/PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of...

JAN : 4.25 (-1.70%)
JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain PR Newswire - Tue Aug 29, 2023

/PRNewswire/ -- JanOne (Nasdaq: JAN), the visionary biotech company dedicated to discovering non-addictive treatments for pain, as well as causes of pain, has...

JAN : 4.25 (-1.70%)
JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting PR Newswire - Fri Aug 25, 2023

/PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of...

JAN : 4.25 (-1.70%)
JanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq Rules PR Newswire - Tue Aug 22, 2023

/PRNewswire/ -- JanOne (Nasdaq: JAN) (the "Company"), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for...

JAN : 4.25 (-1.70%)
JanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq Rules PR Newswire - Fri Aug 18, 2023

/PRNewswire/ -- JanOne (Nasdaq: JAN) (the "Company"), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for...

JAN : 4.25 (-1.70%)
JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting PR Newswire - Fri Aug 18, 2023

/PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of...

JAN : 4.25 (-1.70%)
JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain PR Newswire - Wed Jun 28, 2023

/PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a biopharmaceutical company that is developing multiple drugs to treat chronic diseases like Peripheral Artery...

JAN : 4.25 (-1.70%)
JanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023 PR Newswire - Thu Apr 13, 2023

/PRNewswire/ -- JanOne (Nasdaq: JAN), Dr. Amol Soin, Chief Medical Officer of JanOne, will be presenting at the Appalachian Region Spine and Pain Meeting in...

JAN : 4.25 (-1.70%)
JanOne Welcomes John Bonfiglio -- Veteran Biotech Executive, Deal Maker and Strategist -- to Top Management Team PR Newswire - Thu Mar 23, 2023

/PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of...

JAN : 4.25 (-1.70%)

Barchart Exclusives

Teva Pharmaceuticals Stock Has Unusual Call Options Activity After Its Q1 Results Barchart - 22 minutes ago
Teva Pharmaceuticals, the generic drug maker, posted good Q1 results today, reaffirming its forecast for significant free cash flow in 2024. That led to unusual call options activity based on a Barchart report. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot